Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men

Journal of Infectious Diseases

Volumn 189, Issue 12, 2004, Pages 2213-2219

  Moorthy, Vasee S ^a,b   Imoukhuede, Egeruan B ^a   Keating, Sheila ^b   Pinder, Margaret ^a   Webster, Daniel ^b   Skinner, Michael A ^c   Gilbert, Sarah C ^b   Walraven, Gijs ^a   Hill, Adrian V S ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIGEN; DNA; EPITOPE; MALARIA VACCINE; PLASMID DNA; RECOMBINANT VACCINE; THROMBOSPONDIN;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIGEN SPECIFICITY; ARTICLE; BLISTER; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; FOWLPOX VIRUS; GENE CONSTRUCT; HEADACHE; HUMAN; MALAISE; MALARIA; MALE; NAUSEA; PAIN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VIRUS RECOMBINANT; VIRUS STRAIN; VOMITING;

ADOLESCENT; ADULT; ANIMALS; EPITOPES, T-LYMPHOCYTE; GAMBIA; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 2942624113     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421118     Document Type: Article

References (36)

1. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664-6.
2. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6.
3. Weiss WR, Mellouk S, Houghten RA, et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 1990; 171:763-73.
4. Good MF, Pombo D, Quakyi IA, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988; 85:1199-203.
5. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
6. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991; 88:3300-4.
7. + T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol 1991; 3:997-1003.
8. Hill AV, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434-9.
9. Wizel B, Houghten R, Church P, et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 1995; 155:766-75.
10. Gilbert SC, Plebanski M, Gupta S, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998; 279:1173-7.
11. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64.
12. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18:927-74.
13. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-80.
14. + type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001; 98:10817-22.
15. McConkey S, Reece WHH, Moorthy VS, et al. Enhanced T-cell immunogenicity in humans of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara. Nature Medicine 2003; 9:729-35.
16. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4:397-402.
17. Plebanski M, Gilbert SC, Schneider J, et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:4345-55.
18. Gilbert SC, Schneider J, Plebanski M, et al. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara: comparisons and combinations. Biol Chem 1999; 380:299-303.
19. Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95:7648-53.
20. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15:1280-4.
21. Robson KJ, Hall JR, Jennings MW, et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988; 335:79-82.
22. + t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69:681-6.
23. Hanke T, Samuel RV, Blanchard TJ, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-32.
24. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
25. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
26. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
27. Moorthy VS, Finder M, Reece WH, et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 2003; 188:1239-44.
28. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988; 6:497-503.
29. Mayr A, Malicki K. Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus. Zentralbl Veterinarmed B 1966; 13:1-13.
30. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996; 14:428-34.
31. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-46.
32. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21:1995-2002.
33. Clarke SE, Bogh C, Brown RC, Walraven GE, Thomas CJ, Lindsay SW. Risk of malaria attacks in Gambian children is greater away from malaria vector breeding sites. Trans R Soc Trop Med Hyg 2002; 96:499-506.
34. Lalvani A, Hurt N, Aidoo M, Kibatala P, Tanner M, Hill AV. Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Eur J Immunol 1996; 26:773-9.
35. Plebanski M, Aidoo M, Whittle HC, Hill AV. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 1997; 158:2849-55.
36. Le TP, Coonan KM, Hedstrom RC, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893-901.